Manufacturing of CD19 CAR T-cell products based on CD4/CD8-selected (CAR-T) or CD45RA-depleted T cells (CAR-Tm). (A) Overall CAR-T manufacturing and lymphodepletion plan. (B) Schema of simultaneous donor-derived CAR-T plus haplo HSCT. (C) Transduction efficacy and numbers of T-cell products after the CAR-T or CAR-Tm (CD45RA-depleted) manufacturing. (D) Analysis of frequency of CD4⁺ and CD8⁺ T cells in CAR-Tm and CAR-T products. Dots represent individual patients in panels A, B, and C. Green dots represent CAR-T patients with dominance of CD4⁺ cells. (E) Peripheral blood CAR-Tm and CAR-T persistence. Green dots represent CAR-T patients with dominance of CD4⁺ cells. (F) Patient characteristics, CD19 CAR T-cells (CAR-Tm) application, details, and outcome. For panels C and D, statistical analysis was performed using unpaired t tests. For all panels, ∗P < .05, ∗∗P < .01, ∗∗∗P < .005.